Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers
NCT: NCT07610642 · NOT_YET_RECRUITING
Brief Summary
The AMNIO-BRAIN Trial is a research study looking at whether a simple treatment during labor can help protect a baby's brain. Some newborns develop a condition called hypoxic-ischemic encephalopathy (HIE), which happens when the brain does not get enough oxygen or blood flow. This can lead to serious health problems, including developmental delays and lifelong disabilities. While there is a cooling treatment after birth that can help, it starts only after delivery and may come too late to prevent the earliest stages of injury. Research suggests that some brain injury may actually begin during labor, especially when there is an infection in the uterus called chorioamnionitis. This infection can cause inflammation and fever in the mother, which may increase stress on the baby and affect the baby's brain. This study is testing whether a commonly used labor procedure called amnioinfusion can help. Amnioinfusion involves placing fluid similar to your biologic amniotic fluid into the uterus during labor. It is already used safely in many deliveries for other reasons. In prior research, this treatment slightly lowered the temperature inside the uterus and improved signs that the baby was no longer under stress. In this study, 80 pregnant subjects with chorioamnionitis will be randomly assigned to receive amnioinfusion during labor or receive standard care without amnioinfusion. All patients will continue to receive normal treatment for infection. After delivery, researchers will collect a small sample of blood from the umbilical cord. This blood will be tested for markers that can show whether the baby may have experienced stress or injury to the brain.
Frequently Asked Questions
What is Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers?
Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers is a clinical trial registered under NCT07610642. Current status: NOT_YET_RECRUITING.
What is the status of NCT07610642?
The current status of NCT07610642 (Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers) is: NOT_YET_RECRUITING.
When did Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers start?
Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers started on 2026-07-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.